Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ulodesine · BCX-4208, LR-09

Small molecule · developed by BioCryst Pharmaceuticals

Phase 2 Most advanced trial (none active)

BCRX Developer

3 Registered trials

What is Ulodesine?

Ulodesine (BCX4208) is an oral small molecule studied in gout, hyperuricemia, arthritis, joint disease and renal insufficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BCX-4208, LR-09
Drug type: Small molecule
Therapy area: Musculoskeletal, Renal & urology
Developer: BioCryst Pharmaceuticals (BCRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: JNG8L9460Y

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01407874	Phase 2	Gout	Completed	BCRX
NCT01265264	Phase 2	Gout	Completed	BCRX
NCT01129648	Phase 2	Gout	Completed	BCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ArthritisGoutHyperuricemiaJoint DiseaseRenal Insufficiency

More from BioCryst Pharmaceuticals

Berotralstat FDA approved Peramivir FDA approved Avoralstat Phase 3 BCX10013 Phase 1 BCX17725 Phase 1 Forodesine Phase 1/2 Galidesivir Phase 1 Pelecopan Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BCRX page.

Follow BCRX, the company behind Ulodesine

See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z